Expression profiles of metabolic enzymes and drug transporters in the liver and along the intestine of beagle dogs

Drug Metabolism and Disposition

Volumn 40, Issue 8, 2012, Pages 1603-1610

  Haller, Stephanie ^a   Schuler, Franz ^b   Lazic, Stanley E ^b   Bachir Cherif, Dalila ^b   Krämer, Stefanie D ^a   Parrott, Neil J ^b   Steiner, Guido ^b   Belli, Sara ^b  

^a ETH ZURICH   (Switzerland)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; CARRIER PROTEIN; CYTOCHROME P450 2D15; CYTOCHROME P450 3A12; CYTOCHROME P450 3A26; DRUG METABOLIZING ENZYME; DRUG TRANSPORT PROTEIN; GLUCURONOSYLTRANSFERASE 1A6; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN 1; ORGANIC CATION TRANSPORTER 1; PEPTIDE TRANSPORTER 1; UNCLASSIFIED DRUG;

ABCB1 GENE; ABCC1 GENE; ABCG2 GENE; ANIMAL TISSUE; ARTICLE; COLON; CONTROLLED STUDY; CORRELATION ANALYSIS; CYP2D15 GENE; CYP3A12 GENE; CYP3A26 GENE; DOG; FEMALE; GENE EXPRESSION; INTESTINE; LIVER; MALE; MEMBRANE TRANSPORT; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SLC15A1 GENE; SLC22A1 GENE; TISSUE LEVEL; UGT1A6 GENE;

ANIMALS; DOGS; FEMALE; GENE EXPRESSION PROFILING; INTESTINES; LIVER; MALE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

CANIS FAMILIARIS;

EID: 84863887989     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.112.045443     Document Type: Article

References (57)

1. Amatori FM, Meucci V, Giusiani M, Soldani G, Corazza M, and Giorgi M (2004) Effect of grapefruit juice on the pharmacokinetics of cyclosporine in dogs. Vet Rec 154:180-181.
2. Barber RD, Harmer DW, Coleman RA, and Clark BJ (2005) GAPDH as a housekeeping gene: analysis of GAPDH mRNA expression in a panel of 72 human tissues. Physiol Genomics 21:389-395.
3. Bleasby K, Castle JC, Roberts CJ, Cheng C, Bailey WJ, Sina JF, Kulkarni AV, Hafey MJ, Evers R, Johnson JM, et al. (2006) Expression profiles of 50 xenobiotic transporter genes in humans and pre-clinical species: a resource for investigations into drug disposition. Xenobiotica 36:963-988.
4. Bock KW, Bock-Hennig BS, Münzel PA, Brandenburg JO, Köhle CT, Soars MG, Riley RJ, Burchell B, von Richter O, Eichelbaum MF, et al. (2002) Tissue-specific regulation of canine intestinal and hepatic phenol and morphine UDP-glucuronosyltransferases by beta-naphthoflavone in comparison with humans. Biochem Pharmacol 63:1683-1690.
5. Bogaards JJ, Bertrand M, Jackson P, Oudshoorn MJ, Weaver RJ, van Bladeren PJ, and Walther B (2000) Determining the best animal model for human cytochrome P450 activities: a comparison of mouse, rat, rabbit, dog, micropig, monkey and man. Xenobiotica 30:1131-1152.
6. Bruyere A, Decleves X, Bouzom F, Ball K, Marques C, Treton X, Pocard M, Valleur P, Bouhnik Y, Panis Y, et al. (2010) Effect of variations in the amounts of P-glycoprotein (ABCB1), BCRP (ABCG2) and CYP3A4 along the human small intestine on PBPK models for predicting intestinal first pass. Mol Pharm doi:10.1021/mp100015x.
7. Chen J, Tran C, Xiao L, Palamanda J, Klapmuts T, Kumari P, Lin X, Wang EJ, Gu YZ, Humphries M, et al. (2009) Co-induction of CYP3A12 and 3A26 in dog liver slices by xenobiotics: species difference between human and dog CYP3A induction. Drug Metab Lett 3:61-66.
8. Conrad S, Viertelhaus A, Orzechowski A, Hoogstraate J, Gjellan K, Schrenk D, and Kauffmann HM (2001) Sequencing and tissue distribution of the canine MRP2 gene compared with MRP1 and MDR1. Toxicology 156:81-91.
9. Court MH, Zhang X, Ding X, Yee KK, Hesse LM, and Finel M (2012) Quantitative distribution of mRNAs encoding the 19 human UDP- glucuronosyltransferase enzymes in 26 adult and 3 fetal tissues. Xenobiotica 42:266-277.
10. de Waziers I, Cugnenc PH, Yang CS, Leroux JP, and Beaune PH (1990) Cytochrome P 450 isoenzymes, epoxide hydrolase and glutathione transferases in rat and human hepatic and extrahepatic tissues. J Pharmacol Exp Ther 253:387-394.
11. Ding X and Kaminsky LS (2003) Human extrahepatic cytochromes P450: function in xenobiotic metabolism and tissue-selective chemical toxicity in the respiratory and gastrointestinal tracts. Annu Rev Pharmacol Toxicol 43:149-173.
12. Dressman JB (1986) Comparison of canine and human gastrointestinal physiology. Pharm Res 3:123-131.
13. Dressman JB and Reppas C (2010) Oral Drug Absorption: Prediction and Assessment, 2nd ed, Informa Healthcare, New York.
14. Eguchi K, Nishibe Y, Baba T, and Ohno K (1996) Quantitation of cytochrome P450 enzymes (CYP1A1/2, 2B11, 2C21 and 3A12) in dog liver microsomes by enzyme-linked immunosorbent assay. Xenobiotica 26:755-763.
15. Fraser DJ, Feyereisen R, Harlow GR, and Halpert JR (1997) Isolation, heterologous expression and functional characterization of a novel cytochrome P450 3A enzyme from a canine liver cDNA library. J Pharmacol Exp Ther 283:1425-1432.
16. Greenacre M (1992) Correspondence analysis in medical research. Stat Methods Med Res 1:97-117.
17. Gründemann D, Gorboulev V, Gambaryan S, Veyhl M, and Koepsell H (1994) Drug excretion mediated by a new prototype of polyspecific transporter. Nature 372:549-552.
18. Jonker JW and Schinkel AH (2004) Pharmacological and physiological functions of the polyspecific organic cation transporters: OCT1, 2, and 3 (SLC22A1-3). J Pharmacol Exp Ther 308:2-9.
19. Keenan CM and Vidal JD (2006) Standard morphologic evaluation of the heart in the laboratory dog and monkey. Toxicol Pathol 34:67-74.
20. King CD, Rios GR, Assouline JA, and Tephly TR (1999) Expression of UDP-glucuronosyltransferases (UGTs) 2B7 and 1A6 in the human brain and identification of 5-hydroxytryptamine as a substrate. Arch Biochem Biophys 365:156-162.
21. Komura H and Iwaki M (2008) Species differences in in vitro and in vivo small intestinal metabolism of CYP3A substrates. J Pharm Sci 97:1775-1800.
22. Krämer SD and Testa B (2008) The biochemistry of drug metabolism-an introduction: part 6. Inter-individual factors affecting drug metabolism. Chem Biodivers 5:2465-2578.
23. Kyokawa Y, Nishibe Y, Wakabayashi M, Harauchi T, Maruyama T, Baba T, and Ohno K (2001) Induction of intestinal cytochrome P450 (CYP3A) by rifampicin in beagle dogs. Chem Biol Interact 134:291-305.
24. Locuson CW, Ethell BT, Voice M, Lee D, and Feenstra KL (2009) Evaluation of Escherichia coli membrane preparations of canine CYP1A1, 2B11, 2C21, 2C41, 2D15, 3A12, and 3A26 with coexpressed canine cytochrome P450 reductase. Drug Metab Dispos 37:457-461.
25. Lu H and Klaassen C (2008) Gender differences in mRNA expression of ATP-binding cassette efflux and bile acid transporters in kidney, liver, and intestine of 5/6 nephrectomized rats. Drug Metab Dispos 36:16-23.
26. Martignoni M, Groothuis GM, and de Kanter R (2006) Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction. Expert Opin Drug Metab Toxicol 2:875-894.
27. Martínez-Jiménez CP, Jover R, Donato MT, Castell JV, and Gómez-Lechón MJ (2007) Transcriptional regulation and expression of CYP3A4 in hepatocytes. Curr Drug Metab 8:185-194.
28. McEntee M, Silverman JA, Rassnick K, Zgola M, Chan AO, Tau PT, and Page RL (2003) Enhanced bioavailability of oral docetaxel by co-administration of cyclosporin A in dogs and rats. Vet Comp Oncol 1:105-112.
29. Mealey KL, Jabbes M, Spencer E, and Akey JM (2008) Differential expression of CYP3A12 and CYP3A26 mRNAs in canine liver and intestine. Xenobiotica 38:1305-1312.
30. Mills BM, Zaya MJ, Walters RR, Feenstra KL, White JA, Gagne J, and Locuson CW (2010) Current cytochrome P450 phenotyping methods applied to metabolic drug-drug interaction prediction in dogs. Drug Metab Dispos 38:396-404.
31. Murakami T and Takano M (2008) Intestinal efflux transporters and drug absorption. Expert Opin Drug Metab Toxicol 4:923-939.
32. Nielsen CU, Andersen R, Brodin B, Frokjaer S, and Steffansen B (2001) Model prodrugs for the intestinal oligopeptide transporter: model drug release in aqueous solution and in various biological media. J Control Release 73:21-30.
33. Nielsen CU and Brodin B (2003) Di/tri-peptide transporters as drug delivery targets: regulation of transport under physiological and patho-physiological conditions. Curr Drug Targets 4:373-388.
34. Nielsen CU, Brodin B, Jørgensen FS, Frokjaer S, and Steffansen B (2002) Human peptide transporters: therapeutic applications. Expert Opin Ther Pat 12:1329-1350.
35. Paine MF, Hart HL, Ludington SS, Haining RL, Rettie AE, and Zeldin DC (2006) The human intestinal cytochrome P450 "pie." Drug Metab Dispos 34:880-886.
36. Parrott N and Lave T (2008) Applications of physiologically based absorption models in drug discovery and development. Mol Pharm 5:760-775.
37. Parrott N, Lukacova V, Fraczkiewicz G, and Bolger MB (2009) Predicting pharmacokinetics of drugs using physiologically based modeling-application to food effects. Aaps J 11:45-53.
38. Peters IR, Peeters D, Helps CR, and Day MJ (2007) Development and application of multiple internal reference (housekeeper) gene assays for accurate normalisation of canine gene expression studies. Vet Immunol Immunopathol 117:55-66.
39. Rodríguez-Antona C, Donato MT, Pareja E, Gómez- Lechón MJ, and Castell JV (2001) Cytochrome P-450 mRNA expression in human liver and its relationship with enzyme activity. Arch Biochem Biophys 393:308-315.
40. Rubio-Aliaga I and Daniel H (2008) Peptide transporters and their roles in physiological processes and drug disposition. Xenobiotica 38:1022-1042.
41. Sakamoto K, Kirita S, Baba T, Nakamura Y, Yamazoe Y, Kato R, Takanaka A, and Matsubara T (1995) A new cytochrome P450 form belonging to the CYP2D in dog liver microsomes: purification, cDNA cloning, and enzyme characterization. Arch Biochem Biophys 319:372-382.
42. Seithel A, Karlsson J, Hilgendorf C, Björquist A, and Ungell AL (2006) Variability in mRNA expression of ABC- and SLC-transporters in human intestinal cells: comparison between human segments and Caco-2 cells. Eur J Pharm Sci 28:291-299.
43. Strassburg CP, Kneip S, Topp J, Obermayer-Straub P, Barut A, Tukey RH, and Manns MP (2000) Polymorphic gene regulation and interindividual variation of UDP-glucuronosyltransferase activity in human small intestine. J Biol Chem 275:36164-36171.
44. Taipalensuu J, Törnblom H, Lindberg G, Einarsson C, Sjöqvist F, Melhus H, Garberg P, Sjöström B, Lundgren B, and Artursson P (2001) Correlation of gene expression of ten drug efflux proteins of the ATP-binding cassette transporter family in normal human jejunum and in human intestinal epithelial Caco-2 cell monolayers. J Pharmacol Exp Ther 299:164-170.
45. Testa B and Krämer SD (2007) The biochemistry of drug metabolism-an introduction: Part 2. Redox reactions and their enzymes. Chem Biodivers 4:257-405.
46. Testa B and Krämer SD (2008a) The biochemistry of drug metabolism-an introduction: part 4. Reactions of conjugation and their enzymes. Chem Biodivers 5:2171-2336.
47. Testa B and Krämer SD (2008b) The Biochemistry of Drug Metabolism: Volume 1: Principles, Redox Reactions, Hydrolyses, Verlag Helvetica Chimica Acta/Wiley-VCH, Zürich.
48. Testa B and Krämer SD (2010) The Biochemistry of Drug Metabolism: Volume 2: Conjugations, Consequences of Metabolism, Influencing Factors, Verlag Helvetica Chimica Acta/Wiley-VCH, Zürich.
49. Thörn M, Finnström N, Lundgren S, Rane A, and Lööf L (2005) Cytochromes P450 and MDR1 mRNA expression along the human gastrointestinal tract. Br J Clin Pharmacol 60:54-60.
50. Trepanier LA (2006) Cytochrome P450 and its role in veterinary drug interactions. Vet Clin North Am Small Anim Pract 36:975-985, v.
51. Tukey RH and Strassburg CP (2000) Human UDP-glucuronosyltransferases: metabolism, expression, and disease. Annu Rev Pharmacol Toxicol 40:581-616.
52. Turpeinen M, Ghiciuc C, Opritoui M, Tursas L, Pelkonen O, and Pasanen M (2007) Predictive value of animal models for human cytochrome P450 (CYP)-mediated metabolism: a comparative study in vitro. Xenobiotica 37:1367-1377.
53. Uchaipichat V, Winner LK, Mackenzie PI, Elliot DJ, Williams JA, and Miners JO (2006) Quantitative prediction of in vivo inhibitory interactions involving glucuronidated drugs from in vitro data: the effect of fluconazole on zidovudine glucuronidation. Br J Clin Pharmacol 61:427-439.
54. Wijnholds J (2002) Drug resistance caused by multidrug resistance-associated proteins. Novartis Found Symp 243:69-79; discussion 80-62, 180-185.
55. Zhou SF (2009) Polymorphism of human cytochrome P450 2D6 and its clinical significance: part I. Clin Pharmacokinet 48:689-723.
56. Ziegler TR, Fernández-Estívariz C, Gu LH, Bazargan N, Umeakunne K, Wallace TM, Diaz EE, Rosado KE, Pascal RR, Galloway JR, et al. (2002) Distribution of the H+/peptide transporter PepT1 in human intestine: up-regulated expression in the colonic mucosa of patients with short-bowel syndrome. Am J Clin Nutr 75:922-930.
57. Zuur AF, Walker NJ, Saveliev AA, and Smith GM (2009) Mixed Effects Models and Extensions in Ecology, Springer, New York.